Patient Guide: A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

✓ Get matched to the right study location for you
✓ Connect directly with study coordinators at 67 participating sites
✓ Understand eligibility with our simplified screening tool
✓ Free service - we're here to help you access clinical research

Trial ID: NCTNCT06855771

Status: 🟢 Enrolling Now

Condition: Carcinoma, Non-Small-Cell Lung

Phase: Phase II

Find a Study Location Near You

This study is available at 67 research sites. We'll help you connect with the location that's right for you.

Participating sites include:

• Anchorage, Alaska
• Boston, Massachusetts
• Detroit, Michigan
• And 64 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) - Join Clinical Trial NCTNCT06855771

How to Join This Clinical Trial - NCTNCT06855771

Learn how to participate in this Phase II trial studying an investigational therapy for Carcinoma, Non-Small-Cell Lung. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Carcinoma, Non-Small-Cell Lung. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied: Carcinoma, Non-Small-Cell Lung
Treatment Being Tested: Investigational treatment
Study Phase: Phase II - Safety and effectiveness study
Enrollment Status: Currently enrolling participants
Study Identifier: NCTNCT06855771 - ClinicalTrials.gov Identifier
Sponsored By: Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

Initial screening to determine eligibility
Regular study visits and health assessments
Receiving the study treatment or placebo
Medical monitoring and follow-up care
Contributing to medical research that may help others
Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

Close medical monitoring by healthcare professionals
Access to potential new treatments
Compensation for time and travel (varies by study)
No-cost study-related medical care
The opportunity to help advance medical knowledge

Milwaukee, Wisconsin 53226 - United States

Status: RECRUITING

And 57 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this Phase II clinical trial for Carcinoma, Non-Small-Cell Lung:

Review the eligibility criteria with your healthcare provider
Contact the study team for a pre-screening interview
Schedule an in-person screening visit if eligible
Review and sign the informed consent form
Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

Find clinical trials that match your condition
Get matched to the right study location near you
Connect directly with study coordinators
Understand if you qualify with simplified eligibility screening
Navigate the enrollment process with personalized support
Access new treatments through clinical research participation